Between January and October 2018, Russia imported 78.5 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms 29% higher than that of the same period of 2017. The current dynamics can only be explained by higher prices, because the dynamics in physical terms are -7.3% (9.4 tons of APIs.)

The dynamics of pharmacopoeial API import are +29.5%, while those of the technical API import are only +14.4%. The average price dynamics for both categories were nearly the same, with +39% for pharmacopoeial APIs and +37% for technical APIs. However, the dynamics of technical API import are -16.7%, if calculated in tons.

The import lines have also changed. 41 new trademarks were added to the pharmacopoeial API import line this year, making it 647. As for technical APIs, the import line has expectedly lost 26 trademarks.

Among the top 20 pharmacopoeial APIs, Linezolidum has the highest dynamics in monetary terms, with a 37 times increase. It is mostly imported by Pfizer, starting this October. The production of antibiotic Zivox is localized at the facilities of Russian Polysan, and it commissioned their first lot in November 2018. They signed a contract with an American company back in 2016 and were planning to commission their first products in 2018 (Liprimar, Jakvinus, and Zivox.)

Atazanavirum is still the leader in both the dynamics and import volume among the technical APIs, with an 87 times increase in monetary terms.

Dynamics of pharmacopoeial and technical API import to Russia, customs clearance prices (2015 – 2017, January – October 2018), bln RUB